Changes in the clinical features and prognosis of collagen diseases and their contributing factors: 30 Years of past progress and prospect for the 21 st century in our department

Ryumachi

Volumn 41, Issue 3, 2001, Pages 672-686

  Hashimoto, H ^a  

^a NONE

Author keywords

Changing pattern; Collagen diseases; Rheumatoid arthritis (RA); Systemic lupus erythematosus (SLE); Vasculitis syndrome

Indexed keywords

CLINICAL FEATURE; COLLAGEN DISEASE; CONFERENCE PAPER; HUMAN; JAPAN; MEDICAL SOCIETY; PROGNOSIS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; CAUSE OF DEATH; COLLAGEN DISEASES; CYTOKINES; DIAGNOSTIC TECHNIQUES AND PROCEDURES; FORECASTING; HEALTH EDUCATION; HUMANS; LYMPHOCYTE ACTIVATION; POLYMORPHISM, GENETIC; PROGNOSIS; RETROVIRIDAE; T-LYMPHOCYTES;

EID: 0034916728     PISSN: 03009157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Follow up study on the changes in the clinical features and prognosis of Japanese patients with systemic lupus erythematosus during the past 3 to 4 decades
2. The 1982 revised criteria for the classification of systemic lupus erythematosus
3. American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
4. Mixed connective tissue disease: An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)
5. The anticardiolipin syndrome
6. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β 2-glycoprotein I (apolipoprotein H)
7. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
8. Segmental necrotizing glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology?
9. Nomenclature of systemic vasculitides: Proposal of an International Consensus Conference
10. Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis
11. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus
12. Monthly intravenous cyclophosphamide in the treatment of severe systemic lupus erythematosus
13. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa
14. Systemic lupus erythematosus and congenital anomalies, focusing on neonatal lupus erythematosus and anti-SS-A/SS-B antibodies
15. Association of CD 19 polymorphism with susceptibility to systemic lupus erythematosus
16. The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
17. Identification of the gene loci that predispose to rheumatoid arthritis
18. Comprehensive analysis of HLA genes in Takayasu arteritis in Japan
19. The potential roles of endogenous retroviruses in autoimmunity
20. Quantitative analyses of messenger RNA of human endogenous retrovirus in patients with systemic lupus erythematosus
21. Retroviruses and autoimmunity
22. Endogenous retroviruses in pathogenesis of autoimmunity
23. Immunohistologic analysis of renal CD 40 and CD 40 L expression in lupus nephritis and other glomerulonephritis
24. Reduction of atherosclerosis in mice by inhibition of CD 40 signalling
25. CD 70/CD 27 interactions regulate Ig and autoantibody production in patients with systemic lupus erythematosus
26. Reactivity of anti-proliferating cell nuclear antigen (PCNA) murine monoclonal antibodies and human autoantibodies to the PCNA multiprotein complexes involved in cell proliferation
27. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens
28. Precursor B cell for autoantibody production in genomically Fas-intact autoimmune disease are not subject to Fas-mediated immune elimination
29. The genetics of lupus